Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2011

01.11.2011 | Review Article

Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest

verfasst von: Aram Demirjian, Peter Peng, Jean-Francois H. Geschwind, David Cosgrove, Jacob Schutz, Ihab R. Kamel, Timothy M. Pawlik

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. It is traditionally difficult to cure, especially when discovered at later stages, making early diagnosis and intervention of paramount importance. HCC typically arises in the background of chronic liver disease and can have various morphologic appearances. One of the most difficult of these to recognize on early surveillance imaging is the infiltrative subtype, which can account for up to 13% of all HCC cases, and may be more closely associated with background hepatitis B infection.

Discussion

Certain imaging characteristics can provide vital clues, including differing signal intensity on the T1 and T2 sequences of magnetic resonance imaging (MRI) and the presence/appearance of portal vein thrombus. Owing to the diffuse and infiltrating properties of this tumor, surgical resection and transplantation are rarely if ever viable therapeutic options. Other forms of liver-directed therapy have been attempted with limited success, having minimal efficacy and high morbidity. To date, there is no data available to determine if the various HCC subtypes respond to systemic therapy differently, so this may be the most reasonable approach. Left untreated, observed patients commonly progress to hepatic failure fairly rapidly.

Conclusion

Infiltrative HCC can be extremely subtle, and therefore difficult to detect, especially in the background of cirrhosis. Providers caring for patients with hepatitis, chronic liver disease, and cirrhosis must be extremely vigilant in the evaluation of surveillance imaging in order to potentially discover this HCC subtype as early as possible and initiate a multidisciplinary treatment plan.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74–108.PubMedCrossRef
2.
3.
Zurück zum Zitat Cunningham SC, Tsai S, Marques HP, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 2009; 16(7):1820–31.PubMedCrossRef Cunningham SC, Tsai S, Marques HP, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 2009; 16(7):1820–31.PubMedCrossRef
4.
Zurück zum Zitat Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg; 252(6):903–12. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg; 252(6):903–12.
5.
Zurück zum Zitat Okuda K, Noguchi T, Kubo Y, et al. A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1981; 1(4):280–9.PubMed Okuda K, Noguchi T, Kubo Y, et al. A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1981; 1(4):280–9.PubMed
6.
Zurück zum Zitat Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72(5):1557–63.PubMedCrossRef Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72(5):1557–63.PubMedCrossRef
7.
Zurück zum Zitat Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18(2):189–95.PubMedCrossRef Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18(2):189–95.PubMedCrossRef
8.
Zurück zum Zitat Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286(1):52–9.PubMedCrossRef Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286(1):52–9.PubMedCrossRef
9.
Zurück zum Zitat Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127(5 Suppl 1):S56–61.PubMedCrossRef Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127(5 Suppl 1):S56–61.PubMedCrossRef
10.
Zurück zum Zitat Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994; 91(6):2230–4.PubMedCrossRef Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994; 91(6):2230–4.PubMedCrossRef
11.
Zurück zum Zitat Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22(4 Pt 1):1027–33.PubMedCrossRef Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22(4 Pt 1):1027–33.PubMedCrossRef
12.
Zurück zum Zitat Castells L, Vargas V, Gonzalez A, et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995; 15(3):159–63.PubMed Castells L, Vargas V, Gonzalez A, et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995; 15(3):159–63.PubMed
13.
Zurück zum Zitat Vauthey JN, Walsh GL, Vlastos G, Lauwers GY. Importance of field cancerisation in clinical oncology. Lancet Oncol 2000; 1(1):15–6.PubMedCrossRef Vauthey JN, Walsh GL, Vlastos G, Lauwers GY. Importance of field cancerisation in clinical oncology. Lancet Oncol 2000; 1(1):15–6.PubMedCrossRef
14.
Zurück zum Zitat Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25(27):3834–47.PubMedCrossRef Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25(27):3834–47.PubMedCrossRef
15.
Zurück zum Zitat Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48(1):110–5.PubMedCrossRef Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48(1):110–5.PubMedCrossRef
16.
Zurück zum Zitat Myung SJ, Yoon JH, Kim KM, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006; 53(68):266–70.PubMed Myung SJ, Yoon JH, Kim KM, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006; 53(68):266–70.PubMed
17.
Zurück zum Zitat Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101(3):524–32.PubMedCrossRef Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101(3):524–32.PubMedCrossRef
18.
Zurück zum Zitat Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci; 55(10):2744–55. Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci; 55(10):2744–55.
19.
Zurück zum Zitat Miyaaki H, Nakashima O, Kurogi M, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42(12):962–8.PubMedCrossRef Miyaaki H, Nakashima O, Kurogi M, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42(12):962–8.PubMedCrossRef
20.
21.
Zurück zum Zitat Tada T, Kumada T, Toyoda H, et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25(4):848–53.PubMedCrossRef Tada T, Kumada T, Toyoda H, et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25(4):848–53.PubMedCrossRef
22.
Zurück zum Zitat Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002; 17(7):772–8.PubMedCrossRef Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002; 17(7):772–8.PubMedCrossRef
23.
Zurück zum Zitat Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol; 105(3):610–2. Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol; 105(3):610–2.
24.
Zurück zum Zitat Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S133–43.PubMedCrossRef Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S133–43.PubMedCrossRef
25.
Zurück zum Zitat de Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14(2):159–65.PubMedCrossRef de Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14(2):159–65.PubMedCrossRef
26.
Zurück zum Zitat Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247(2):311–30.PubMedCrossRef Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247(2):311–30.PubMedCrossRef
27.
Zurück zum Zitat Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38(4):1034–42.PubMed Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38(4):1034–42.PubMed
28.
Zurück zum Zitat Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180(2):455–60.PubMed Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180(2):455–60.PubMed
29.
Zurück zum Zitat Kim YK, Han YM, Kim CS. Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 2009; 70(1):94–100.PubMedCrossRef Kim YK, Han YM, Kim CS. Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 2009; 70(1):94–100.PubMedCrossRef
30.
Zurück zum Zitat Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology; 254(1):154–62. Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology; 254(1):154–62.
31.
Zurück zum Zitat Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140(5):450–7; discussion 57–8PubMedCrossRef Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140(5):450–7; discussion 57–8PubMedCrossRef
32.
Zurück zum Zitat Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137(4):403–10.PubMedCrossRef Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137(4):403–10.PubMedCrossRef
33.
Zurück zum Zitat Han YS, Choi DL, Park JB. Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation—eighteen months of follow-up: a case report. Transplant Proc 2008; 40(8):2835–6.PubMedCrossRef Han YS, Choi DL, Park JB. Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation—eighteen months of follow-up: a case report. Transplant Proc 2008; 40(8):2835–6.PubMedCrossRef
34.
Zurück zum Zitat Ochiai T, Sonoyama T, Ichikawa D, et al. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol 2004; 130(4):197–202.PubMedCrossRef Ochiai T, Sonoyama T, Ichikawa D, et al. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol 2004; 130(4):197–202.PubMedCrossRef
35.
Zurück zum Zitat Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology; 52(2):762–73. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology; 52(2):762–73.
36.
Zurück zum Zitat Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5):1164–71.PubMedCrossRef Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5):1164–71.PubMedCrossRef
37.
Zurück zum Zitat Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734–9.PubMedCrossRef Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734–9.PubMedCrossRef
38.
Zurück zum Zitat Lopez RR, Jr., Pan SH, Hoffman AL, et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137(6):653–7; discussion 57–8PubMedCrossRef Lopez RR, Jr., Pan SH, Hoffman AL, et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137(6):653–7; discussion 57–8PubMedCrossRef
39.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4):378–90.PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4):378–90.PubMedCrossRef
Metadaten
Titel
Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest
verfasst von
Aram Demirjian
Peter Peng
Jean-Francois H. Geschwind
David Cosgrove
Jacob Schutz
Ihab R. Kamel
Timothy M. Pawlik
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1614-7

Weitere Artikel der Ausgabe 11/2011

Journal of Gastrointestinal Surgery 11/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.